Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Telephone:||+44 (0)1223 760 339|
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise offers support to all of the University’s research fields, from science, technology, engineering, maths and medicine to the arts, humanities and social sciences. It is through us that many of the University’s inventions and ideas are protected, licences and consultancy contracts are negotiated, and funding is acquired by start-ups and spin-outs.
A small consultancy project enabled by Cambridge Enterprise has blossomed over a short space of time into a major new initiative to develop and commercialise greener and more efficient light emitting diodes (LEDs).
12 March 2019Read in full
Two of the most innovative US universities, along with their UK counterparts, will meet with the minister and innovation and industrial strategy leaders from UK government today (Monday 25 February).
25 February 2019Read in full
Paul Bailey, one of Cambridge’s most influential entrepreneurs and Executive Chairman of Bailey Fisher, has joined Cambridge Enterprise, the commercialisation arm of the University of Cambridge, as an Entrepreneur in Residence.
29 January 2019Read in full
Cambridge Enterprise and the Maxwell Centre are jointly hosting the University of Cambridge exhibit at AutoMobili-D 2019, within the North American International Auto Show in Detroit yhis week (14-17 January).
16 January 2019Read in full
Morphogen-IX Ltd, a University of Cambridge spin-out biotechnology company focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), has announced completion of a £18.4 million ($23.2m) round of financing.
19 December 2018Read in full
Colorifix, a company that has developed the first commercial biological dyeing process, has raised a Series A round of $3 million from impact and strategic investors with strong links to the fashion industry. The round was led by Challenger 88, with participation from Cambridge Enterprise, H&M CO:LAB (part of H&M Group) and Primera Impact.
18 December 2018Read in full
Morphogen-IX Ltd, a biotechnology spin-out from Cambridge Enterprise that is focused on the development of bone morphogenetic proteins (BMPs) for the treatment of pulmonary arterial hypertension (PAH), announced the nomination of its clinical development candidate and initiation of formal preclinical development.
4 December 2018Read in full
Poro Technologies, which is developing next-generation LED technology, has won the £20,000 first prize in the 2018 Cambridge Enterprise and Entrepreneurial Postdocs of Cambridge (EPOC) Postdoc Business Plan Competition.
6 November 2018Read in full
Astellas Pharma Inc. and Quethera Limited have announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma.
14 August 2018Read in full
Twelve semi-finalists have been named in the 2018 Postdoc Business Plan Competition run by Cambridge Enterprise in conjunction with the Entrepreneurial Postdocs of Cambridge (EPOC).
1 August 2018Read in full